Evidence map›Paper›PMID 41280800›Full record

ArticleACS omega2025

A Glucosylated BODIPY Uses the GLUT Channel to Target Cancer Cells in

Marta Turati, Giacomo Biagiotti, Cosetta Ravelli, Chiara Tobia, Jacopo Cardellini, Luca Mignani, Jacopo Tricomi, Debora Berti, Stefano Cicchi, Barbara Richichi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marta TuratiDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25121, Italy.
Giacomo BiagiottiDepartment of Chemistry "Ugo Schiff", University of Firenze, Via della Lastruccia 13, Sesto Fiorentino, Fi 50019, Italy.
Cosetta RavelliDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25121, Italy.
Chiara TobiaDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25121, Italy.
Jacopo CardelliniDepartment of Chemistry "Ugo Schiff", University of Firenze, Via della Lastruccia 13, Sesto Fiorentino, Fi 50019, Italy.
Luca MignaniDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25121, Italy.
Jacopo TricomiDepartment of Chemistry "Ugo Schiff", University of Firenze, Via della Lastruccia 13, Sesto Fiorentino, Fi 50019, Italy.
Debora BertiDepartment of Chemistry "Ugo Schiff", University of Firenze, Via della Lastruccia 13, Sesto Fiorentino, Fi 50019, Italy.ORCID https://orcid.org/0000-0001-8967-560X
Stefano CicchiDepartment of Chemistry "Ugo Schiff", University of Firenze, Via della Lastruccia 13, Sesto Fiorentino, Fi 50019, Italy.ORCID https://orcid.org/0000-0002-4913-6414
Barbara RichichiDepartment of Chemistry "Ugo Schiff", University of Firenze, Via della Lastruccia 13, Sesto Fiorentino, Fi 50019, Italy.ORCID https://orcid.org/0000-0001-7093-9513
Roberto RoncaDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25121, Italy.ORCID https://orcid.org/0000-0001-8979-7068

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The conjugation of fluorescent probes to tumor-targeting molecules represents a promising strategy for the development of precision cancer bioimaging and treatment. Among the different tumor-targeting strategies, the use of d-glucose residues, which exploit the high energy demand of cancer cells, can enable recognition by a broad spectrum of tumors, thus overcoming limitations related to cancer heterogeneity. In this study, we combined the distinctive optical properties of BODIPY-based probes with the known tumor-targeting abilities of d-glucose. We report on the characterization of a glucosylated BODIPY, named

Identifiers

PMID41280800
PMCPMC12631688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.